";s:4:"text";s:5089:" Always consult your healthcare provider.No known alcohol/food interactions. The manuscript was written in its entirety by the authors.Of 1283 subjects screened, 762 were randomly assigned to treatment (The primary efficacy end point — a serum urate concentration of less than 6.0 mg per deciliter at the last three measurements — was reached by 53 percent of the subjects taking 80 mg of febuxostat, 62 percent of those taking 120 mg of febuxostat, and 21 percent of those taking allopurinol (P<0.001 for each febuxostat group vs. the allopurinol group) (By week 2 of the study (the first visit after randomization), the proportion of subjects with serum urate concentrations of less than 6.0 mg per deciliter was significantly higher in the groups receiving febuxostat than in the group receiving allopurinol (P<0.001) (The percentage of subjects in each interval is calculated by dividing the number of subjects with at least one gout flare in that interval by the number of subjects exposed to at least one dose of drug in that interval. Fisher, Jr. (Newport News, Va.), D. Fitz-Patrick (Honolulu), F.D. This website also contains material copyrighted by 3rd parties. Although the incidence of gout flares diminished with continued treatment, the overall incidence during weeks 9 through 52 was similar in all groups: 64 percent of patients receiving 80 mg of febuxostat, 70 percent of those receiving 120 mg of febuxostat, and 64 percent of those receiving allopurinol (P=0.99 for 80 mg of febuxostat vs. allopurinol; P=0.23 for 120 mg of febuxostat vs. allopurinol). Adamson III (San Diego, Calif.), C.G. The area of the tophus was then calculated by multiplying the two measurements.The primary efficacy end point was a serum urate concentration of less than 6.0 mg per deciliter at each of the last three monthly measurements. Allopurinol rated 7.6/10 vs Febuxostat rated 8.3/10 in overall patient satisfaction. Grober (Evanston, Ill.), C.S. ), T. Isakov (Lyndhurst, Ohio), A.M. Jackson (Bartlett, Tenn.), A.T. Kaell (Port Jefferson Station, N.Y.), S.P. By week 52, the median percentage reduction in tophus area was 83 percent for subjects receiving 80 mg of febuxostat, 66 percent for those receiving 120 mg of febuxostat, and 50 percent for those receiving allopurinol. Allopurinol is used in the treatment of high uric acid levels associated with gout, kidney stones, and cancer treatment. Pareigis (Moline, Ill.), R.Z. To comment please Comments on Medscape are moderated and should be professional in tone and on topic. Prepare to become a physician, build your knowledge, lead a health care organization, and advance your career with NEJM Group information and services.Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, is a potential alternative to allopurinol for patients with hyperuricemia and gout.We randomly assigned 762 patients with gout and with serum urate concentrations of at least 8.0 mg per deciliter (480 μmol per liter) to receive either febuxostat (80 mg or 120 mg) or allopurinol (300 mg) once daily for 52 weeks; 760 received the study drug. Karlock (Austintown, Ohio), R.M. Prescribed for Gout.